Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple inhaler help both lungs and heart in new COPD patients?

NCT ID NCT06072690

Disease control Sponsor: Lithuanian University of Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a dual bronchodilator (a combination inhaler) can improve breathing, heart function, and quality of life in people newly diagnosed with moderate-to-severe COPD. Researchers will measure changes in exercise capacity and lung function over 12 weeks. The trial aims to enroll 80 adults aged 40 and older who have a significant smoking history.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dual bronchodilator (a combination of two inhaled drugs to open airways)
What this could lead to
If successful, this could show that starting with dual bronchodilation soon after diagnosis improves both lung function and heart health in COPD patients.
What could go wrong
This is a small, early-stage study with only 80 participants, so results may not apply to all COPD patients. The treatment is already approved, so the main question is whether it offers extra heart benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The cohort will be selected from patients with clinical signs of COPD reffered to the tertiary care outpatient clinic by general physicians from the primary and secondary care clinics.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 40 years and older * Smoking index of 10 pack-years and more * Newly diagnosed chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 30-79 percent of predicted and forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC) less than 70 percent of predicted. Exclusion Criteria: * Active lung infection * Present or previously treated lung cancer * Alpha-1 antitrypsin deficiency * Diagnosed interstitial lung disease * Previously diagnosed asthma * Diagnosed chronic hypercapnic respiratory failure * Treatment with systemic glucocorticoids * Unstable ischaemic heart disease * Pregnancy * Present cardiac arrhythmias * Uncontrolled arterial hypertension * Dementia and other mental states that determine patient's inability to consent * Other medical conditions that in the opinion of the investigator disqualify the subject for inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Chronic obstructive pulmonary disease moderate Chronic obstructive pulmonary disease severe Quality of life

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lithuanian University of Health Sciences

    RECRUITING

    Kaunas, Kaunas County, 44307, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.